IMTXのROE（自己資本利益率）は？

IMMATICS NVのROEは-46.99%です。

IMTXの配当利回りは？

IMMATICS NVの配当利回りは0.00%です。

IMTXの品質スコア（Quality Score）は？

当社のAIはIMTXの総合財務品質を100点中0点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

IMTXは今が買い時ですか？

当社AIのタイミングスコアは100点中27点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

IMTXはどのセクターに属しますか？

IMMATICS NVはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）

IMTX (NASDAQ) 株価分析 | IMMATICS NV

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

IMTX AI Analysis Summary

Our AI summary for IMTX: IMMATICS NV (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -46.99%, a dividend yield of 0.00%. Its financial Quality Score stands at 0/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

IMTX

IMMATICS NV

US:NASDAQ STOCK Healthcare >> Biotechnology News 70

USD 8.66

-0.54 (-5.87%) Day Change

Watchlist Portfolio Compare Chart

0.01

D/E

-47.0%

ROE

-39.4%

ROA

0.00%

Div Yield

IMMATICS NV
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 8.66 Price -0.54 (-5.87%) Day Change	NEWS SCORE: 70

IMTX, ファンダメンタルスコアはnot good ( ファンダメンタル = 0) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

0 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...

Deepscope 分析

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	70
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	8.66
PBV / Sector	2.76 / 5.20
Earning Per Share	-1.48

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	3.81 M GREAT
Average 1W Daily Value	5.75 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-574.86 / 98.71
NPM Average (%) / Sector	-226.01 / -1,721.76
NPM Change Average (%) / Sector	-1,314.90 / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-39.42 / 27.02
ROA Average (%) / Sector	-16.40 / -368.17
ROA Change Average (%) / Sector	-526.05 / 5,404.12
ROE (%) / Sector	-46.99 / 3.47
ROE Average (%) / Sector	-22.09 / 6.51
ROE Change Average (%) / Sector	-517.19 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

登録情報

Analyze Date	2026-08-01 08:00:00
Symbol	IMTX
Name	IMMATICS NV
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	136.67 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1,257.39 / 9,903.94

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Paul-Ehrlich-Strasse 15-19, Tübingen, Germany, 72076

Phone: 49 7071 5397 0

Website: https://www.immatics.com

Employees: 678

Sector: Healthcare >> Biotechnology

Description: Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.